Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy

Aredo, JV; Mambetsariev, I; Hellyer, JA; Amini, A; Neal, JW; Padda, SK; McCoach, CE; Riess, JW; Cabebe, EC; Naidoo, J; Abuali, T; Salgia, R; Loo, BW; Diehn, M; Han, SS; Wakelee, HA

Wakelee, HA (corresponding author), Stanford Univ, Dept Med, Div Oncol, Stanford Canc Inst,Sch Med, 875 Blake Wilbur Dr, Stanford, CA 94305 USA.

JOURNAL OF THORACIC ONCOLOGY, 2021; 16 (6): 1030

Abstract

Methods: We conducted a multi-institutional retrospective analysis of patients with unresectable stage III EGFR-mutated NSCLC who completed concurrent......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索